http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Chin Kook Rhee ),( Ki-suck Jung ),( Kwang Ha Yoo ) 대한결핵 및 호흡기학회 2020 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.128 No.-
Background The Korea Chronic Obstructive Pulmonary Disorders Subgroup Study Team (Korea COPD Subgroup Study team, KOCOSS) is a multicenter observational study that includes more than 2,000 patients who were enrolled from 54 hospitals in Korea. Baseline characteristics and exacerbation data have been recently updated. Methods Baseline characteristics including age, sex, body mass index (BMI), lung function, COPD assessment test (CAT), St. George’s Respiratory Questionnaire (SGRQ)-C, blood eosinophil, and medications were collected. Patients were prospectively followed and information regarding exacerbation for one year was collected. Results Total number of patients enrolled was 2,181. Age was 69.0 ± 7.7 (mean ± standard deviation) and 2,030 (93.1%) were male. Mean FEV1 was 1.62L (56.0%) and FVC 3.22 (78.9%). Mean CAT score was 14.5 ± 8.1. Blood eosinophil count was 226.1 ± 248.2. Among 2,012 patients, 739 (36.7%) were prescribed inhaled corticosteroid plus long acting beta2 agonist (ICS+LABA), 1,015 (50.4%) long acting muscarinic antagonist (LAMA), and 434 (21.6%) LABA+LAMA. Phosphodiesterases 4 inhibitor was prescribed in 143 (7.1%) patients. Mean annual rate of moderate exacerbation was 0.90 ± 1.76 and severe was 0.17 ± 0.65. Conclusions Here we report recent updated characteristics of patients with COPD in KOCOSS cohort. These will be valuable fundamental sources for further COPD research in Korea. This work was supported by the Research Program funded by the Korea Centres for Disease Control and Prevention (2014- P33003-00).
Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease
Chin Kook Rhee,Deog Kyeom Kim 대한내과학회 2020 The Korean Journal of Internal Medicine Vol.35 No.2
Phosphodiesterase-4 inhibitors (PDE4Is) are potent anti-inf lammatory agents and roflumilast has been used to prevent acute exacerbation of chronic obstructive pulmonary disease (COPD). Roflumilast decreases neutrophil migration, restores cystic fibrosis transmembrane conductance regulator activity, and recovers glucocorticoid effects. A forced expiratory volume in 1 second of < 50%, a chronic bronchitis phenotype, high blood eosinophil levels, and a history of hospitalization are biomarkers for predicting responses to roflumilast. Adverse effects are common in clinical practice. An inhaled PDE4I has recently been developed and is under clinical trial. CHF6001 and RPL554 exhibit promise and may be future treatment options for COPD.
REVIEW : The Korean Cough Guideline: Recommendation and Summary Statement
( Chin Kook Rhee ),( Ji Ye Jung ),( Sei Won Lee ),( Joo Hee Kim ),( So Young Park ),( Kwang Ha Yoo ),( Dong Ah Park ),( Hyeon Kyoung Koo ),( Yee Hyung Kim ),( Ina Jeong ),( Je Hyeong Kim ),( Deog Kyeo 대한결핵 및 호흡기학회 2016 Tuberculosis and Respiratory Diseases Vol.79 No.1
Cough is one of the most common symptom of many respiratory diseases. The Korean Academy of Tuberculosis and Respiratory Diseases organized cough guideline committee and cough guideline was developed by this committee. The purpose of this guideline is to help clinicians to diagnose correctly and treat efficiently patients with cough. In this article, we have stated recommendation and summary of Korean cough guideline. We also provided algorithm for acute, subacute, and chronic cough. For chronic cough, upper airway cough syndrome (UACS), cough variant asthma (CVA), and gastroesophageal reflux disease (GERD) should be considered. If UACS is suspicious, first generation anti-histamine and nasal decongestant can be used empirically. In CVA, inhaled corticosteroid is recommended in order to improve cough. In GERD, proton pump inhibitor is recommended in order to improve cough. Chronic bronchitis, bronchiectasis, bronchiolitis, lung cancer, aspiration, angiotensin converting enzyme inhibitor, habit, psychogenic cough, interstitial lung disease, environmental and occupational factor, tuberculosis, obstructive sleep apnea, peritoneal dialysis, and idiopathic cough can be also considered as cause of chronic cough. Level of evidence for treatment is mostly low. Thus, in this guideline, many recommendations are based on expert opinion. Further study regarding treatment for cough is mandatory.
Summary of Korean Asthma Guideline
( Chin Kook Rhee ),( Ji Yong Moon ),( Hyonsoo Joo ),( Ji Ye Jung ),( Jung-kyu Lee ),( Kyung Hoon Min ),( Hyeon-kyoung Koo ),( Seong Yong Lim ),( Hyoung Kyu Yoon ),( Sang Yeub Lee ) 대한결핵 및 호흡기학회 2023 Tuberculosis and Respiratory Diseases Vol.86 No.3
Asthma is a chronic inflammatory airway disease that is characterized by variable airflow obstruction. The Korean Asthma Study Group of the Korean Academy of Tuberculosis and Respiratory Diseases has recently updated the Korean Asthma Guideline. This review summarizes the updated Korean Asthma Guideline. Asthma prevalence is increasing worldwide, and in Korea. Variable airflow obstruction can be confirmed by bronchodilator response or other tests, and should be established prior to the controller medication. A low-dose inhaled corticosteroid-formoterol is used to alleviate symptoms in all treatment step, and it can be used as a controller as well as reliever in steps 3-5. This approach is preferred, because it reduces the risk of severe exacerbations, compared to the use of short-acting β2-agonist as reliever. In severe asthma, phenotype/ endotype based on the underlying inflammation should be evaluated. For type 2 severe asthma, the biologics should be considered.
The Korean Cough Guideline: Recommendation and Summary Statement
Rhee, Chin Kook,Jung, Ji Ye,Lee, Sei Won,Kim, Joo-Hee,Park, So Young,Yoo, Kwang Ha,Park, Dong Ah,Koo, Hyeon-Kyoung,Kim, Yee Hyung,Jeong, Ina,Kim, Je Hyeong,Kim, Deog Kyeom,Kim, Sung-Kyoung,Kim, Yong H The Korean Academy of Tuberculosis and Respiratory 2016 Tuberculosis and Respiratory Diseases Vol.79 No.1
Cough is one of the most common symptom of many respiratory diseases. The Korean Academy of Tuberculosis and Respiratory Diseases organized cough guideline committee and cough guideline was developed by this committee. The purpose of this guideline is to help clinicians to diagnose correctly and treat efficiently patients with cough. In this article, we have stated recommendation and summary of Korean cough guideline. We also provided algorithm for acute, subacute, and chronic cough. For chronic cough, upper airway cough syndrome (UACS), cough variant asthma (CVA), and gastroesophageal reflux disease (GERD) should be considered. If UACS is suspicious, first generation anti-histamine and nasal decongestant can be used empirically. In CVA, inhaled corticosteroid is recommended in order to improve cough. In GERD, proton pump inhibitor is recommended in order to improve cough. Chronic bronchitis, bronchiectasis, bronchiolitis, lung cancer, aspiration, angiotensin converting enzyme inhibitor, habit, psychogenic cough, interstitial lung disease, environmental and occupational factor, tuberculosis, obstructive sleep apnea, peritoneal dialysis, and idiopathic cough can be also considered as cause of chronic cough. Level of evidence for treatment is mostly low. Thus, in this guideline, many recommendations are based on expert opinion. Further study regarding treatment for cough is mandatory.